Subscribe
Israel-Hamas Conflict
NFL
Donald Trump
Floods
US Economy
Kamala Harris
Immigration
San Francisco 49ers
US Immigration
Volleyball
US Politics
Golf
Soccer
Published

Sanofi wins US approval for drug combination to treat multiple myeloma

Summary by WTVB
Sanofi won approval for the use of a drug combination with its Sarclisa infusion to treat certain types of newly diagnosed multiple myeloma, where it has previously been used only after standard treatments have failed, the U.S. Food and Drug Administration said on Friday. The French drugmaker, a market leader in anti-inflammatory drugs, has underscored its commitment to oncology drug development even after a once-promising breast cancer drug can…

0 Articles

All
Left
Center
Right
WTVBWTVB

Sanofi wins US approval for drug combination to treat multiple myeloma

Sanofi won approval for the use of a drug combination with its Sarclisa infusion to treat certain types of newly diagnosed multiple myeloma, where it has previously been used only after standard treatments have failed, the U.S. Food and Drug Administration said on Friday. The French drugmaker, a market leader in anti-inflammatory drugs, has underscored its commitment to oncology drug development even after a once-promising breast cancer drug can…

Read Full Article
onclive.comonclive.com

FDA Approves Isatuximab Plus VRd for Newly Diagnosed, Transplant-Ineligible Multiple Myeloma

The FDA has approved isatuximab plus bortezomib, lenalidomide, and dexamethasone for newly diagnosed, transplant-ineligible myeloma.

Read Full Article
Endpoints NewsEndpoints News

Sanofi's Sarclisa gets approved as a first-line option for some patients newly diagnosed with multiple myeloma

Despite largely exiting oncology, Sanofi continues to reap the benefit of its multiple myeloma treatment Sarclisa. The FDA on Friday approved the anti-CD38 treatment as a first-line option for patients who have been recently diagnosed but are not eligible for an autologous stem cell transplant. The French pharma said it’s

Read Full Article
DataemiaDataemia

FDA approves isatuximab-irfc combination for certain adults with multiple myeloma

The FDA approved the use of isatuximab-irfc in combination with bortezomib, lenalidomide, and dexamethasone for the treatment of certain adults with multiple myeloma who are not eligible for stem cell transplantation. This approval was based on results from a phase 3 trial showing a significant reduction in disease progression and death with isatuximab-irfc. Common side effects of this treatment include upper respiratory tract infection, diarrhe…

Read Full Article
ajmc.comajmc.com

FDA Approves Isatuximab With VRd as First-Line Option for Transplant-Ineligible Multiple Myeloma

Isatuximab (Sarclisa) with bortezomib, lenalidomide, and dexamethasone (VRd) is now an approved option for adults who cannot receive an autologous stem cell transplant to treat their newly diagnosed multiple myeloma.

Read Full Article
abbonews.comabbonews.com

Sanofi (NASDAQ: SNY) Secures FDA Approval for Multiple Myeloma Drug in Newly Diagnosed Patients

On Friday, the U.S. Food and Drug Administration said it has approved the use of a drug combination along with Sanofi's (NASDAQ: SNY) Sarclisa infusion as a

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources are Center
100% Center
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Sources are mostly out of (0)

Similar News Topics

United StatesUnited States
Trending Topics
Ground News logo
App Store IconPlay Store Icon
CompanyAboutHistoryMissionBlogTestimonialsGroup SubscriptionsSubscribeGiftFree TrialCareersAffiliates
HelpHelp CenterFAQContact UsFor Educators/LibrariesMedia Bias RatingsOwnership and Factuality RatingsReferral CodeNews SourcesTopics
ToolsAppBrowser ExtensionDaily NewsletterBlindspot Report NewsletterBurst Your Bubble NewsletterTimelines
DonatePrivacy PolicyManage CookiesTerms and Conditions
© 2024 Snapwise Inc
News
For You
Search
BlindspotLocal